Sodium Bicarbonate (sodium bicarbonate)

Where it stands

Sodium Bicarbonate (sodium bicarbonate) solution from Baxter Healthcare Corp is approved in the US. The official record shows an FDA approval on 2026-08-14 under NDA218524, classified as a "new formulation or manufacturer".

This is the second recent approval of a sodium bicarbonate solution in the records. Amneal's product (NDA220790) was approved on 2026-07-09 with the same classification, about five weeks earlier. The records also list another US-approved Sodium Bicarbonate entry for the same substance.

The records give no therapeutic area and no indication text, so this analysis cannot say which clinical uses the Baxter label covers. They also give no strength, container, route of administration or presentation details beyond "solution".

Regulatory pathway and designations

The only designation in the records is "New formulation or manufacturer". It is a classification of the approval type. It is not an expedited-program designation such as orphan, priority review or breakthrough, and none of those appear in the records.

The CHMP opinion date is blank, as expected for a US-only record. Nothing here involves the EU centralised procedure, and no EU status is reported. The FDA approval is the only regulatory event listed for Baxter.

The records do not state the specific NDA submission type (for example, whether it relied on published literature or a reference product), the review timeline, a PDUFA date or any post-marketing commitments. Anything on those points would be speculation. Two separate NDAs for sodium bicarbonate solutions from different sponsors within weeks of each other show that several manufacturers can hold approved applications for this established substance.

Safety and pharmacovigilance

The records contain no safety information. They have no label warnings, adverse event data, REMS, boxed warning or post-marketing requirements, so no product-specific safety assessment is possible from them.

As general procedure, the holder of an approved US NDA must meet FDA post-marketing safety reporting obligations. These include expedited reporting of serious, unexpected adverse drug experiences and periodic safety reporting. Product quality and manufacturing-related reports are also relevant for a manufacturer-specific approval. Whether any additional requirement applies to this NDA is not in the records.

Professionals who need the safety profile should read the approved prescribing information and FDA review documents once available, rather than relying on this record.

What to watch

First, check the approved labeling for NDA218524. It will settle the indication, strength, presentation and any differences from the Amneal product and the other US-approved sodium bicarbonate entry.

Second, watch for further approvals or supplements for sodium bicarbonate. The July and August 2026 approvals suggest an active period for this substance. The records do not explain why, and they do not show any supply, shortage or market context.

Third, the records show no launch date, commercial availability or EU or other regional filings for Baxter's product. Those would need to come from company or regulator announcements.